Pulmonary vascular dysfunction secondary to pulmonary arterial hypertension: Insights gained through retrograde perfusion

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 314, Issue 5, 2018, Pages L835-L845

  Zhou, Chun ^a,b   Crockett, Edward S ^a,b   Batten, Lynn ^b   McMurtry, Ivan F ^a,b   Stevens, Troy ^a,b  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Edema; Plexiform lesions; Pulmonary hypertension; Semaxanib (Sugen 5416); Vascular resistance

Indexed keywords

ANIMAL; COMPLICATION; FISCHER 344 RAT; LUNG CIRCULATION; MALE; PATHOPHYSIOLOGY; PERFUSION; PHYSIOLOGY; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; VASCULAR DISEASE; VASODILATATION;

ANIMALS; HYPERTENSION, PULMONARY; MALE; PERFUSION; PULMONARY ARTERY; PULMONARY CIRCULATION; RATS; RATS, INBRED F344; VASCULAR DISEASES; VASODILATION;

EID: 85054848798     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/AJPLUNG.00201.2017     Document Type: Article

References (47)

1. Abe K, Shinoda M, Tanaka M, Kuwabara Y, Yoshida K, Hirooka Y, McMurtry IF, Oka M, Sunagawa K. Haemodynamic unloading reverses occlusive vascular lesions in severe pulmonary hypertension. Cardiovasc Res 111: 16 –25, 2016. doi:10.1093/cvr/cvw070.
2. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 121: 2747–2754, 2010. doi:10.1161/CIRCULATIONAHA.109.927681.
3. Alzoubi A, Almalouf P, Toba M, O’Neill K, Qian X, Francis M, Taylor MS, Alexeyev M, McMurtry IF, Oka M, Stevens T. TRPC4 inactivation confers a survival benefit in severe pulmonary arterial hypertension. Am J Pathol 183: 1779 –1788, 2013. doi:10.1016/j.ajpath.2013.08.016.
4. Anonymous. Proceedings of the 4th World Symposium on Pulmonary Hypertension, February 2008, Dana Point, California, USA. J Am Coll Cardiol 54, Suppl: S1–S117, 2009.
5. Burrowes KS, Clark AR, Marcinkowski A, Wilsher ML, Milne DG, Tawhai MH. Pulmonary embolism: predicting disease severity. Philos Trans A Math Phys Eng Sci 369: 4255–4277, 2011. doi:10.1098/rsta.2011. 0129.
6. Chaudhary KR, Taha M, Cadete VJ, Godoy RS, Stewart DJ. Proliferative versus degenerative paradigms in pulmonary arterial hypertension: have we put the cart before the horse? Circ Res 120: 1237–1239, 2017. doi:10.1161/CIRCRESAHA.116.310097.
7. Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 28: 434–442, 1997. doi:10.1016/S0046-8177(97)90032-0.
8. Cool CD, Stewart JS, Werahera P, Miller GJ, Williams RL, Voelkel NF, Tuder RM. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 155: 411–419, 1999. doi:10.1016/S0002-9440(10)65137-1.
9. Dawson CA, Jones RL, Hamilton LH. Hemodynamic responses of isolated cat lungs during forward and retrograde perfusion. J Appl Physiol 35: 95–102, 1973. doi:10.1152/jappl.1973.35.1.95.
10. Dawson CA, Jones RL, Hamilton LH. A pulmonary circulation model based on forward and retrograde perfusion of isolated lungs. J Appl Physiol 35: 103–110, 1973. doi:10.1152/jappl.1973.35.1.103.
11. Fesler P, Pagnamenta A, Vachiéry JL, Brimioulle S, Abdel Kafi S, Boonstra A, Delcroix M, Channick RN, Rubin LJ, Naeije R. Single arterial occlusion to locate resistance in patients with pulmonary hypertension. Eur Respir J 21: 31–36, 2003. doi:10.1183/09031936. 03.00054202.
12. Foshat M, Boroumand N. The evolving classification of pulmonary hypertension. Arch Pathol Lab Med 141: 696–703, 2017. doi:10.5858/arpa.2016-0035-RA.
13. Francis CM, Oshima K, Bagjaeo N, Jeon D, Labat S, Oka M, Stevens T. Three-dimensional characterization of occlusive lesions in pulmonary arterial hypertension. FASEB J 31: 1016.1013, 2017.
14. Francis M, Xu N, Zhou C, Stevens T. Transient receptor potential channel 4 encodes a vascular permeability defect and high-frequency Ca2+ transients in severe pulmonary arterial hypertension. Am J Pathol 186: 1701–1709, 2016. doi:10.1016/j.ajpath.2016.02.002.
15. Galambos C, Sims-Lucas S, Abman SH, Cool CD. Intrapulmonary bronchopulmonary anastomoses and plexiform lesions in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 193: 574 –576, 2016. doi:10.1164/rccm.201507-1508LE.
16. Guyton AC, Lindsey AW. Effect of elevated left atrial pressure and decreased plasma protein concentration on the development of pulmonary edema. Circ Res 7: 649–657, 1959. doi:10.1161/01.RES.7.4.649.
17. Hakim TS, Kelly S. Occlusion pressures vs. micropipette pressures in the pulmonary circulation. J Appl Physiol (1985) 67: 1277–1285, 1989. doi:10.1152/jappl.1989.67.3.1277.
18. Hargett LA, Hartman LJ, Scruggs AK, McLendon JM, Haven AK, Bauer NN. Severe pulmonary arterial hypertensive rats are tolerant to mild exercise. Pulm Circ 5: 349–355, 2015. doi:10.1086/681267.
19. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43, Suppl S: 13S–24S, 2004. doi:10.1016/j.jacc.2004.02.029.
20. Jiang B, Deng Y, Suen C, Taha M, Chaudhary KR, Courtman DW, Stewart DJ. Marked strain-specific differences in the SU5416 rat model of severe pulmonary arterial hypertension. Am J Respir Cell Mol Biol 54: 461–468, 2016. doi:10.1165/rcmb.2014-0488OC.
21. Jones PL, Rabinovitch M. Tenascin-C is induced with progressive pulmonary vascular disease in rats and is functionally related to increased smooth muscle cell proliferation. Circ Res 79: 1131–1142, 1996. doi:10. 1161/01.RES.79.6.1131.
22. Kafi SA, Mélot C, Vachiéry JL, Brimioulle S, Naeije R. Partitioning of pulmonary vascular resistance in primary pulmonary hypertension. J Am Coll Cardiol 31: 1372–1376, 1998.
23. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, Yuan JX, Weir EK. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 54, Suppl: S20 –S31, 2009. doi:10.1016/j.jacc. 2009.04.018.
24. Ochoa CD, Stevens T. Studies on the cell biology of interendothelial cell gaps. Am J Physiol Lung Cell Mol Physiol 302: L275–L286, 2012. doi:10.1152/ajplung.00215.2011.
25. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, Voelkel NF, McMurtry IF. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 100: 923–929, 2007. doi:10.1161/01.RES. 0000261658.12024.18.
26. Ota H, Beutz MA, Ito M, Abe K, Oka M, McMurtry IF. S1P(4) receptor mediates S1P-induced vasoconstriction in normotensive and hypertensive rat lungs. Pulm Circ 1: 399–404, 2011. doi:10.4103/2045-8932.87309.
27. Rai PR, Cool CD, King JA, Stevens T, Burns N, Winn RA, Kasper M, Voelkel NF. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 178: 558 –564, 2008. doi:10.1164/rccm. 200709-1369PP.
28. Reeves JT, Groves BM, Turkevich D. The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis 134: 342–346, 1986. doi:10.1164/arrd.1986.134.2.342.
29. Rol N, Timmer EM, Faes TJ, Vonk Noordegraaf A, Grünberg K, Bogaard HJ, Westerhof N. Vascular narrowing in pulmonary arterial hypertension is heterogeneous: rethinking resistance. Physiol Rep 5: e13159, 2017. doi:10.14814/phy2.13159.
30. Schäfer M, Myers C, Brown RD, Frid MG, Tan W, Hunter K, Stenmark KR. Pulmonary arterial stiffness: toward a new paradigm in pulmonary arterial hypertension pathophysiology and assessment. Curr Hypertens Rep 18: 4, 2016. doi:10.1007/s11906-015-0609-2.
31. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62, Suppl: D34–D41, 2013. doi:10.1016/j.jacc.2013.10.029.
32. Solodushko V, Parker JC, Fouty B. Pulmonary microvascular endothelial cells form a tighter monolayer when grown in chronic hypoxia. Am J Respir Cell Mol Biol 38: 491–497, 2008. doi:10.1165/rcmb.2007-0127OC.
33. St Croix CM, Steinhorn RH. New thoughts about the origin of plexiform lesions. Am J Respir Crit Care Med 193: 484 –485, 2016. doi:10.1164/rccm.201510-1959ED.
34. Stenmark KR, Rabinovitch M. Emerging therapies for the treatment of pulmonary hypertension. Pediatr Crit Care Med 11, Suppl: S85–S90, 2010. doi:10.1097/PCC.0b013e3181c76db3.
35. Stevens T. Functional and molecular heterogeneity of pulmonary endothelial cells. Proc Am Thorac Soc 8: 453–457, 2011. doi:10.1513/pats. 201101-004MW.
36. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15: 427–438, 2001. doi:10.1096/fj.00-0343com.
37. Townsley MI, King JA, Alvarez DF. Ca2+ channels and pulmonary endothelial permeability: insights from study of intact lung and chronic pulmonary hypertension. Microcirculation 13: 725–739, 2006. doi:10. 1080/10739680600930362.
38. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144: 275–285, 1994.
39. Tuder RM, Stacher E, Robinson J, Kumar R, Graham BB. Pathology of pulmonary hypertension. Clin Chest Med 34: 639–650, 2013. doi:10. 1016/j.ccm.2013.08.009.
40. Tuder RM, Voelkel NF. Plexiform lesion in severe pulmonary hypertension: association with glomeruloid lesion. Am J Pathol 159: 382–383, 2001. doi:10.1016/S0002-9440(10)61705-1.
41. Urboniene D, Haber I, Fang YH, Thenappan T, Archer SL. Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 299: L401–L412, 2010. doi:10.1152/ajplung.00114.2010.
42. Voelkel NF, Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 8: 2129–2138, 1995. doi:10.1183/09031936.95.08122129.
43. Wagenvoort CA, Wagenvoort N, Draulans-Noë Y. Reversibility of plexogenic pulmonary arteriopathy following banding of the pulmonary artery. J Thorac Cardiovasc Surg 87: 876–886, 1984.
44. Yi ES, Kim H, Ahn H, Strother J, Morris T, Masliah E, Hansen LA, Park K, Friedman PJ. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med 162: 1577–1586, 2000. doi:10.1164/ajrccm.162.4.9912131.
45. Zaidi SH, You XM, Ciura S, Husain M, Rabinovitch M. Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation 105: 516–521, 2002. doi: 10.1161/hc0402.102866.
46. Zhao YD, Courtman DW, Ng DS, Robb MJ, Deng YP, Trogadis J, Han RN, Stewart DJ. Microvascular regeneration in established pulmonary hypertension by angiogenic gene transfer. Am J Respir Cell Mol Biol 35: 182–189, 2006. doi:10.1165/rcmb.2005-0115OC.
47. Zhou C, Townsley MI, Alexeyev M, Voelkel NF, Stevens T. Endothelial hyperpermeability in severe pulmonary arterial hypertension: role of store-operated calcium entry. Am J Physiol Lung Cell Mol Physiol 311: L560 –L569, 2016. doi:10.1152/ajplung.00057.2016.